BTS 71091

Drug Profile

BTS 71091

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Obesity therapies
  • Mechanism of Action Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 24 Jan 2013 Discontinued - Preclinical for Obesity in United Kingdom (PO)
  • 29 Aug 2003 No development reported - Preclinical for Obesity in United Kingdom (PO)
  • 26 Jan 2000 Preclinical development for Obesity in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top